financetom
Business
financetom
/
Business
/
Cue Biopharma Enters License Deal With ImmunoScape for Next-Generation Cell Therapy for Solid Tumors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cue Biopharma Enters License Deal With ImmunoScape for Next-Generation Cell Therapy for Solid Tumors
Nov 13, 2025 11:41 AM

02:02 PM EST, 11/13/2025 (MT Newswires) -- Cue Biopharma ( CUE ) entered an exclusive licensing deal giving ImmunoScape access to its clinical-stage Immuno-STAT molecules for oncology, ImmunoScape said Thursday.

The deal includes a total upfront payment of $15 million, with $10 million in fiscal Q4 and $5 million in November 2026, and gives Cue Biopharma ( CUE ) a 40% equity stake in ImmunoScape, according to a statement from Cue Biopharma ( CUE ) on Wednesday.

ImmunoScape said it will use the assets to advance its "Seed-and-Boost" platform, which is designed to expand cancer-targeting T cells in the body.

ImmunoScape also announced board additions, including Cue Biopharma ( CUE ) chief executive officer Usman Azam and immunotherapy veteran Adrian Bot, and appointed medical oncologist Pamela Munster to its scientific advisory board.

Shares of Cue Biopharma ( CUE ) were up 6% in recent Thursday trading.

Price: 0.71, Change: +0.04, Percent Change: +6.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved